DentaFilm Acquires Makervision to Expand Leadership in Oral CBCT Market

On August 21, the merger and acquisition signing ceremony between Hefei Dentafilm Medical Equipment Co., Ltd. (hereinafter referred to as “Dentafilm”) and Anhui Maikeshi Technology Co., Ltd. (hereinafter referred to as “Maikeshi”) was held at Dentafilm’s headquarters, marking Maikeshi’s official status as a subsidiary of Dentafilm and its integration into the corporate family.

Lu Jianhua, Chairman of Maikeshi; Hu Gongyin, Legal Representative of Maikeshi; Zhu Ruibing, Management Representative of Maikeshi; Huang Kaixian, CEO of Dentafilm; Wang Jun, Director Representative of Dentafilm; Wan Xiaobing, Deputy General Manager of the Marketing Center at Dentafilm; Fang Yong, Director of the R&D Center at Dentafilm; Cai Jingjing, Deputy Director of the Management Center at Dentafilm; and others attended the signing ceremony.

A high-tech enterprise centered on digital imaging technology, specializing in the development of intelligent dental equipment and a full-industry-chain digital cloud platform. The team comprises top-tier, senior R&D professionals from the industry, with R&D centers established in Hefei, Shenzhen, and Suzhou. It has jointly established advanced medical equipment centers and X Laboratories with multiple research universities. The company has completed multiple rounds of financing, attracting investment from several listed companies and state-owned platforms, and has successively received numerous honors, including National High-Tech Enterprise, Specialized, Refined, Differential, and Innovative (SRDI) Enterprise, and one of China’s Top 500 Hidden Unicorns.

Located in the High-Tech Zone of Hefei, the company was founded in May 2019 by a group of senior experts in the field of digital medical imaging. At its inception, it received angel investment from the Hefei High-Tech Zone Government Guidance Fund and the Anhui Fulitong Incubation Fund. Guided by technological innovation and built upon a digital medical imaging technology platform, the company is dedicated to the research, development, and intelligent manufacturing of dental medical imaging products, data storage centers, and supporting management software.

Huang Kaixian, CEO of Dentafilm, stated that this merger will leverage the synergistic advantages of both parties’ resources. Significant synergies will be realized in upstream procurement, R&D technology, product manufacturing, and product line extension, thereby enhancing the competitiveness of Dentafilm’s CBCT in terms of supply chain costs, market customer service coverage, and product portfolio composition.

Hu Gongyin, the legal representative of Maikeshi, expressed high expectations for post-merger development. He stated that Dentafilm is a highly promising enterprise with a stable and innovative management team, demonstrating strong competitiveness in technological innovation, product development, and market management. He believes that the synergistic advantages generated by the merger will undoubtedly bring greater development opportunities to Maikeshi.

CBCT is widely used in oral and maxillofacial surgery, endodontics, dental implant surgery, temporomandibular joint disorders, and other fields. Since its market launch in 2021, Dentafilm’s CBCT products have formed a comprehensive portfolio covering various fields of view and feature numerous highlights, including the integration of AI-powered smart diagnostic and therapeutic technologies.

Within just two years, Dentafilm’s CBCT products have surged to the forefront of market share, a testament to their competitiveness in China’s dental sector and their direct challenge to the core markets traditionally dominated by industry leaders. This acquisition will further strengthen Dentafilm’s product portfolio and market position in the CBCT field, better meeting diverse customer needs.

“RMB 10 billion in revenue, RMB 100 billion in market capitalization” is Dentafilm’s vision and goal for the future market landscape.

CBCT product business share plays a key role in this strategic planning. In the face of different competition and demand in the CBCT market, the extension of the product line is particularly important.

With the completion of the Dentafilm Oral Care Industrial Park, the annual production line for 10,000 CBCT units is also poised to commence operations. It is foreseeable that this acquisition will trigger a reshuffling of the CBCT market, and Dentafilm will leverage this opportunity to further demonstrate the competitive strength of its CBCT products within the industry.